^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ICG122

    i
    Other names: ICG122, ICG-122, CD4CAR, ICG 122
    Associations

    News

    Trials
    Company:
    iCell Gene Therap
    Drug class:
    CD4-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Huda Salman | Trial completion date: Dec 2040 --> Dec 2041 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    ICG122
    over1year
    CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Huda Salman | Trial completion date: Dec 2037 --> Dec 2040
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    ICG122
    almost2years
    Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov)
    P1, N=30, Recruiting, Huda Salman | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    ICG122
    2years
    Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Huda Salman | Initiation date: Oct 2023 --> Jan 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD4 (CD4 Molecule)
    |
    ICG122
    over2years
    CD4CAR T Cell Therapy as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Huda Salman
    New P1 trial • CAR T-Cell Therapy
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD4 (CD4 Molecule) • CD14 (CD14 Molecule) • FOXP3 (Forkhead Box P3)
    |
    ICG122
    3years
    CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Huda Salman | Active, not recruiting --> Recruiting
    Enrollment open
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    ICG122
    over3years
    Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells. (PubMed, Front Immunol)
    Additionally, infusion led to the depletion of CD4+ Treg cells and expansion of CD3+CD8+ T cells and NK cells. These results suggest that CD4-IL15/IL15sushi CAR T cells may be a safe and effective treatment for patients with relapsed or refractory T-cell lymphomas, where new treatment options are needed.
    Journal • CAR T-Cell Therapy
    |
    CD4 (CD4 Molecule) • IL15 (Interleukin 15)
    |
    ICG122
    over3years
    CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Huda Salman | Trial primary completion date: Dec 2022 --> Dec 2025
    Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    ICG122
    4years
    CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Huda Salman | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    ICG122
    over6years
    First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma (ASH 2019)
    An alemtuzumab safety switch has also been established to ensure the elimination of CAR T cells following tumor eradication...Patient received a total dose of 3x10^6 /kg single dose CAR T cells, following which fluconazole and valacyclovir were administrated for infection prophylaxis...Conclusion Our first-in-human clinical trial demonstrates promising efficacy of CD4 CAR T cell therapy in treating patients with refractory Sezary syndrome. cCAR is able to eradicate leukemia blasts, exerting a profound tumor killing effect that is superior to traditional chemotherapies.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8)
    |
    Campath (alemtuzumab) • ICG122 • valacyclovir